PLK1 (Iliaki et al., 2021), EPHK10, and KIF4A also play important roles as prognostic indicators or as targeted therapy sites for the progression of multiple tumors, such as pancreatic cancer (Zhu et al., 2021), esophageal squamous cell carcinoma (Li et al., 2021), bladder cancer (Zheng et al., 2021), and lung cancer (Kirienko et al., 2021). Here, PLK1 is linked to lung carcinoma.